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Polymer-drug conjugates have been intensively investigated for several decades, and even though their 
clinical success still lags behind the promise many researchers have placed in them, they are a mainstay in 
the fields of polymer therapeutics or nanomedicine. For many in the field, the seminal perspective paper 
by Helmut Ringsdorf from 1975 marks the beginning of this field of research. With more than one thousand 
citations, this paper has indubitably affected and inspired generations of researchers in the field, including 
the author of this translation. However, it is not the first paper describing the concept of polymer-drug 
conjugates. Some twenty years earlier, Horst Jatzkewitz described in two outstanding papers probably the 
historically first polymer-drug conjugates, detailed its synthesis, characterization and even first in vivo 
experiments. The results, carefully re-interpreted through the eyes of a scientist of the 21st century, clearly 
highlight several issues that need to be taken into consideration when designing polymer-drug conjugates. 
However, despite the pioneering nature of this paper, it is all but forgotten by the scientific community. In 
the author’s opinion, Horst Jatzkewitz and these papers clearly did not receive the attention and praise they 
deserve. Whether this was because this paper was clearly ahead of it´s time, or because it was published in 
German language, or for some other reason, we cannot know. However, this paper is, in my opinion, an 
excellent piece of work that should be known more widely and available to students and experts world-
wide, which is why the author decided to translate it. Also, to give some more context and also to help 
understand some outdated terms or concepts, additional comments and explanations are added 




On the introduction of physiologically active substances into a colloidal plasma expander 
Introduction of a mezcalin-peptide conjugate into poly(vinyl pyrrolidin) 
 
Horst Jatzkewitz 
Klinisches Institut der Deutschen Forschungsanstalt für Psychiatrie, München, Germany 
Hoppe-Seyler´ s Zeitschrift für physiologische Chemie 1954, 297, (1), 149-156. 
 
Mezcaline, applied to healthy humans, is well-known to exhibit psychic changes similar to those found in 
some psychoses. The similarity in its psychological effect 
is in accordance with the similarity in the chemical 
structure of mezcaline and that of biogenic amines. This 
fact led to a theory of formation of endogenic 
psychoses(1) and led to the investigation on the 
behavior of mezcaline in the organism(2). 
Block and co-workers found that mezcaline is 
incorporated into liver proteins. Therefore, the 
organism is capable to synthesize amineproteins and, 
how was also established by Block(3,4), degrade it(3). 
Considering the chemical structure of amineproteins (Box 1), one might expect a mezcaline amidation of 
the acidic amino acids (glutamic acid and aspartic acid) or the C-terminus of the peptide chain. 
 It is the purpose of the present work to produce such a mezcaline-peptide and a mezcaline-protein 
like substance and to investigate their degradation in vivo and in vitro. Hereby, we understand as a mezcalin-
protein like substance the synthetic introduction of a mezcaline peptide derivative (glycyl-L-leucyl-
mezcaline) into the blood plasma expander polyvinylpyrrolidon (PVP, Box 2). The accordingly modified PVP 
shall at the same time serve as a model for a novel class of potentially therapeutically important depot 
substances1. 
                                                        
1 Several decades ahead of the field, Jatzkewitz clearly understood the potential of polymer-drug conjugates! 
Box 1: Block and co-workers found, using 14C 
labelled mescaline, that the molecule was 
incorporated covalently into proteins in the 
liver after injection. The mescaline-modified 
liver protein was therefore termed 
amineprotein (original: aminprotein). 




 The plasma expander called “Persiton” contains PVP of a molar mass of about 30 kg/mol. 
Macromolecules of a size of 50 – 60 kg/mol can be retained in the organism over months or years2 and may, 
due to their special binding capability for certain physiologically active compounds as depots(5)3. However, 
it also must be possible to obtain a depot effect by covalently binding physiologically active substances by 
an enzymatically cleavable linker to PVP. This is described in the following for a PVP-glycyl-L-leucyl-mezcalin 
conjugate. Maybe, this allows the access of a depot form of a substance like histamine (and mezcalin?), that 
otherwise does not show an affinity to PVP(6) and thereby further study the biochemical behavior of such 
peptide-like conjugated biogenic amines. Experiments in this direction that also include substances of the 
Arterenol-type, Serotonin, physiologically active amino acids and peptides such as thyroxin or peptide 
hormones should be conducted, as far as this is possible without much effort.4 
 The PVP-glycyl-L-leucyl-mezcaline derivative was obtained as described below (Scheme 1): 
 
 
a) Synthesis of glycyl-L-leucyl-mezcaline hydrochloride 
Following a method by Biossonnas(7), carbobenzoxy-glycin (Cbz-gly) was reacted with ethyl 
chloroformiate and the obtained the mixed anhydride I was reacted with L-leucine ethyl ester to 
obtained the corresponding dipeptide ester. This intermediate was without purification converted 
to the carbobenzoxy-glycyl-L-leucine hydrazide II using hydrazine hydrate (45 % yield with respect 
to Cbz-glycine). The product had a melting point of 125-127 °C. Via the corresponding azide and its 
reaction with mezcaline, carboxy-glycyl-L-leucyl-mezcaline (III), with a melting point of 127 °C was 
obtained with 57 % yield. Reductive elimination of the Cbz and treatment with hydrochloric acid 
yielded 94% of glycyl-L-leucyl-mezcaline-hydrochloride (IV), a colorless, glassy, very bitter tasting5 
substance with [alpha]27D : -56.2 ± 1 ° (4.2 % in water). Purity was verified using paper 
chromatography and elemental analysis. 
 
b) Synthesis of a copolymer of vinyl pyrrolidone and acrylic acid.(8) 
                                                        
2 Of course we have learned a lot about retention of (synthetic) macromolecules since Jatzkewitz´ time. 
Retention in the blood stream and different organs depends on many different factors and the molar mass is 
only one of them. Charge, hydrophilicity/hydrophobicity, polymer architecture and hydrodynamic volume are 
others. 
3 Although it is unknown what Jatzkewitz is exactly referring to here, it seems apparent that this means to refer 
to non-covalent entrapment/binding of active substances in form of a complex or other non-covalent 
interactions. 
4 Although not mentioning small molecule drugs specifically, Jatzkewitz does suggest here a range of different 
pharmacologically acive substance, clearly pointing out the potential of this polymer-drug conjugate approach. 
5 back at this time, it was common to taste new compounds, this practice, of course, has been abandoned 
since. 
Box 2: In the 1940 and 1950ties, PVP was 
used as a plasma expander to after 
massive blood loss. This application of 
PVP has led to significant side effects, in 
the PVP storage disease leading to so-
called pseudo-tumors, in which non-
excretable PVP is forming depots. It is 
now known that PVP of a molar mass > 20 
kg/mol cannot be fully excreted. Of 
course, it is important to consider the 
dispersity of the polymer. At the time, 
only free radical polymerization was 
known, leading to products with a 
dispersity of PVP of about 2. Such 
polymer will contain a very significant 
portion of very high molar mass (see 
Tutorial Figure 1) 


















































N-Vinylpyrrolidon (V = VP) was copolymerized 
with 14 % methyl acrylate (MA) (VI) using 
hydrogen peroxide and ammonia as initiators 
in water at approximately 100 °C according to 
Puetzer and colleagues(9). The copolymer 
P(VP-co-MA) VII, constituting a gel, was 
saponified in aqueous sodium hydroxide at 20 
°C and the low molar mass constituents 
removed by dialysis. The high molar mass 
hydrolyzed copolymer P(VP-co-AA6) VIII was 
obtained as a colorless powder in 73% yield 
(with respect to V + VI) which yields a clear 
aqueous solution. The pH value of an aqueous 
solution of P(VP-co-AA) was found to be 5. 
Titration using n/10 aqueous sodium 
hydroxide was employed to determine the 
amount of titratable carboxylic acids. 
Assuming that the polymer composition 
corresponded with the monomer 
composition, 86 % of all ester groups were 
hydrolyzed7. 
 
c) Conjugation of Glycyl-L-leucyl-mezcalin 
(IV = Gly-leu-mez) to P(VP-co-AA) 
 
The conjugation of the mezcalin-dipeptide 
was performed, similar as the peptide 
coupling itself, using the method of 
Biossonnas(7). The mixed anhydride of P(VP-co-AA) and ethyl chloroformiate was obtained in DMF using 
tributylamine as HCl scavenger. IX was obtained according to Scheme 2. 
 
The PVP-mezcaline conjugate X was dialyzed against n/40-HCl and water to remove low molar mass 
impurities. The product contained still 37% of the original free carboxylic acids. With respect to VIII, the 
                                                        
6 Through hydrolysis, the MA becomes acrylic acid, AA in short. 
7 For the sake of clarity, we draw the polymer to be fully hydrolysed in Scheme 2. However, the reader should 
keep in mind that in fact instead of 14 mol% carboxylic acids, the polymer comprises on average 12 mol% 
carboxylic acids and 2 mol% methyl acrylate units (corresponding to 86 % of hydrolysis). The non-hydrolysed 
methyl acrylate units naturally remain in the polymer throughout and exert their hydrophobic character. 
 
 
Tutorial Figure 1: Simulated PVP molar mass distribution 
for Mn = 20 kg/mol, presented as weight fractions 
obtained from Schulz-Zimm distribution functions. For 
the two different distributions, different chain coupling 
coefficients (1 (black) and 5 (grey), respectively) were 
used, resulting in dispersity values of 2 and 1.2, 
respectively. Regions which are expected to yield 
different extend of renal excretion are color coded. 
Polymer chains lying in the green area should be cleared 
rapidly via the kidneys, while polymers in the orange area 
will show delayed clearance. Polymer molecules that lie 
in the red area are expected to show very long retention 
or cannot be cleared at all via the kidneys. 




obtained yield was 50%. The product is partially soluble in water, partially forming a fine, stable emulsion 
(Box 3).  
The successful conjugation of the mezcaline-peptide derivative to the copolymer was proven by paper 
chromatography and infrared spectroscopy. 
 
Figure 1: IR spectra of Abb. 1) Polyvinylpyrrolidone, Abb. 2) copolymer of vinyl pyrrolidone and acrylic 
acid VIII, Abb. 3) glycyl-L-leucyl-mezcaline, covalently attached to a copolymer of vinyl pyrrolidone and 
acrylic acid X and  Abb. 4) glycyl-L-leucyl-mezcaline hydrochloride IV. 
Box 3: These short comments highlights the practical issues with the heterogeneity of the this first 
polymer-drug conjugate. Being synthesized through free radical polymerization, the polymer contains 
fractions that are significantly enriched in MA units (see also Box 4). While the synthesized polymer 
presents as a gel, the hydrolyzed polymer forms a clear solution by itself, as the acrylic acid units are of 
course hydrophilic when deprotonized. However, as they eventually end up conjugated with mezcaline, 
these repeat units again render the product water insoluble. On the other hand, the polymer contains 
fractions of polymer chains, which are basically PVP homopolymer, which may contain a few MA units. 
Accordingly, these polymers will end up with much fewer (if any) mezcaline molecules conjugated to it. 
Therefore, due to the synthetic limitations at the time, Jatzkewitz ends up with a rather insoluble 
polymer-drug conjugate fraction with a large amount of active component but poor solubility and a well-




The high molecular mezcaline-polymer conjugate X was compared to a mixture of VIII and IV using paper 
chromatography in two solvent systems. The peptidic component was detected by ninhydrin only in the 
mixture. The polymer bound peptide give a positive ninhydrin test only after acidic hydrolysis. The 
mezcaline-peptide-polymer conjugate X was compared to the control polymer VIII, both were subjected to 
hydrolysis conditions and the product analyzed by paper chromatography. The mezcaline-peptide-polymer 
conjugate X yielded the glycine and leucine spot. In contrast, mezcaline was completely degraded under 
these conditions (6 N HCl, 115 °C, 16 h)(10). The analysis of the infrared spectra of the four products, PVP 
(Fig. 1, Abb. 1), P(VP-co-AA) (Fig. 1, Abb. 2), X (Fig. 1, Abb. 3) and glycyl-leucyl-mezcalin HCl (Fig. 1, Abb. 4) 
yielded the following: 
 
The IR spectra of the mezcaline-polymer conjugate (solid in KBr) shows two bands in the C=O region at 6.03 
and 6.12 µ8. The band at shorter wavelength is attributed to the carbonyl stretch band of the pyrrolidone 
moiety as the spectra of PVP show a band at the same position. At 6.12 µ, the C=O stretch of the peptide 
carbonyl is observed. In the free glycyl-leucyl-mezcaline, this band is observed at 6.10 µ. Comparing the 
mezcaline ether band (8.95 µ) in the spectra of glycyl-leucyl-mezcaline and the polymer conjugate X, one 
finds 9 ± 2 pyrrolidone moieties per peptide moiety. For comparison, using the percentage of converted 
carboxylic acids, a ratio of 10:1 was obtained. 
 
As was mentioned before, the drug-peptide-polymer conjugate X partially dissolves in water, but partially 
forms a milky emulsion. The emulsion can be precipitated by centrifugation at 30.000 rpm for 15 min. The 
supernatant contained 45% of the material as determined after removal of the water. The fraction did not 
contain free carboxylic acids and showed only about one tenth of the expected glycin and leucine content 
after acid hydrolysis9, as determined by paper chromatography. Moreover, the IR spectra resembled that 
of pure PVP. This shows that during copolymerization of VP and MAA, initially the acrylate polymerizes 
preferentially. There are several possibilities to prevent this and to adjust the monomer consumption. 
Experiments towards this end shall be conducted (Box 4).  
[…] 




The synthesis of glycyl-L-leucyl-mezcaline is 
described. The mezcaline peptide derivative is 
convalently attached to a copolymer of 
vinylpyrrolidone and methyl acrylate. The 
conjugation was achieved through the carboxylates 
of the copolymer, which consists of 89% of 
vinylpyrrolidone repeat units. The possible 
relevance of the polymer-peptide conjugate as 
prototype of a class of enzymatically degradable, 
biologically active compounds, which can regulate 
the residence time of small bioactive molecules in 





                                                        
8 please note, this is the wavelength of the IR-band in micrometer. 
9 please refer again to Box 3 in this context. As only one tenth of the amount of mezcaline is found and the 
initially hydrolyzed polymer contained 12% carboxylates, the soluble fraction contains only about 1% of 
mezcaline unis. At such low content, it is not surprising that the IR essentially resembles that of pure PVP. 
Box 4: Indeed, the copolymerization parameters of 
VP (rVP ≈ 0.1) and MA (rMA ≈ 4-5) are vastly different, 
meaning that the MA polymerizes much faster 
compared to VP. This, in combination with the free 
radical polymerization leads to the situation that the 
polymers formed initially will contain much more 
MA that would be expected from the stoichiometry 
of the reaction, while the polymer chains formed 
later during the reaction will essentially be VP 
homopolymers, as most of the MA will already have 
reacted. In contrast, if this reaction were to be 
carried out using reversible deactivation radical 
polymerization, the resulting polymers would have 
a pronounced gradient or even pseudo-block 
copolymer architecture. In any case, this work 
shows very nicely how important it is to understand 
the polymerization kinetics and copolymerization 





A blood plasma expander (poly vinylpyrrolidon) conjugated peptide-drug derivative (Glycyl-L-leucyl-
mezcalin) as novel depot for biologically active primary amines (mezcalin) 
Horst Jatzkewitz,  
Klinisches Institut der Deutschen Forschungsanstalt für Psychiatrie, München, Germany 
Zeitschrift für Naturforschung 1955, 10, (1), 27-31. 
 
 
Abstract: Mezcaline hydrochloride, glycyl-L-leucyl-mezcalin hydrochloride and a polymer conjugate of 
glycyl-L-leucyl-mezcaline to a copolymer of vinylpyrrolidone and acrylic acid (P(VP-co-AA)) was injected s.c. 
and i.p. At different time intervals, the basic degradation products (mezcaline) in the urine were quantified. 
The injected amount of mezcaline was equal (1.7 mg) in all groups, so that the excretion of mezcaline 
correlates with the residence time of the biogenic amine in the organism. While the two low molar mass 
compounds were excreted within 16 h, mezcaline could be detected even after 17 days after s.c. of the 
mezcaline-peptide-polymer conjugate. These findings are viewed in the light of pharmacology, pharmacy, 
biochemistry and psychiatry. 
 
 
Mezcaline, the biogenic amine found in several cacti, is well known to cause psychological changes after 
administration to healthy humans which are similar to those found in some psychoses(11). Block and co-
workers found that a fraction of the applied mezcalin is incorporated into a liver protein(3,4). About 80% 
of the applied dose is excreted via renal excretion unmetabolized, as both mice and human can metabolize 
mezcalin only poorly. The product of the incorporation into the liver proteins was not isolated nor 
characterized in more detail. 
Inspired by this investigation we have prepared a peptide-drug conjugate – glycyl-L-leucyl-mezcaline, as 
described previously(12). Furthermore, to make it more protein-like, we have covalently conjugated it to a 
colloidal plasma expander, namely a copolymer of vinylpyrrolidone and acrylic acid (P(VP-co-AA)) with a 
broad molar mass distribution10. Both peptamine as well as the polymer conjugate (I, see Scheme 1) were 
synthesized to gain insight into the biochemical behavior of peptide-like conjugates of native/biogenic 
physiologically active compounds of the primary amine type11. It was assumed that I may represent a novel 





Scheme 1: Structure of the polymer conjugate I, prepared by conjugation of glycyl-L-leucyl-mezcaline 
peptamin and P(VP-co-AA)(12). 
 
 
                                                        
10 this is of course quite the opposite of “protein-like” as proteins do not suffer from any molar mass 
distribution 




The hypothesis is based on the fact that I is a conjugate of a non-physiological, high molar mass carrier, 
which guarantees a long residence time in the organism, to which the active compound is bound via a 
physiological linker, i.e. a dipeptide. The active compound should therefore be enzymatically released in 
the living organism, if the peptamine is cleaved in vivo12. 
 
To investigate this, white mice were injected s.c. and i.p. with i) 2 mg of mezcaline hydrochloride (mez-HCl), 
ii) 3.4 mg (glycyl-L-leucyl-mezcalin-hydrochloride (gly-leu-mez-HCl), iii) a mixture of the macromolecular 
carrier (P(VP-co-AA)) (16 mg) and 3.4 mg of gly-leu-mez-HCl, iv) 20 mg of the macromolecular linker with a 
biodegradable linker (I) and v) 24 mg of a conjugate with a non-degradable linker (P(VP-co-AA-co-mez)).13 
All substances yield clear solutions in water at neutral pH. The amount injected was chosen so that all 
animals received 1.7 mg mezcalin. The basic excretion products in the animal´s urine were analyzed at 
different time intervals, for which we used the paper chromatographic analysis method for basic addictive 
drugs developed by us(13). This method is not quantitative but does reflect the quantitative ratio [between 










From the ascending paper chromatograms of the extracts of the white mice´s urine after s.c. injection (Fig. 
1), the following is apparent: 
1. Mezcaline is the only basic metabolite detected if mezcaline or mezcaline-peptamine was 
administered. 
2. If one compares the amounts of excreted mezcaline in the urine pooled for 4 hours after injection 
of mezcaline and mezcaline-dipeptide, no difference is observed. After 16 h (urine pooled 16 -20 h 
p.i.), the excreted amount is below the detection limit (3 ɣ). 
3. Also after injection of a mixture of mezcaline-dipeptide and P(VP-co-AA) no significantly different 
result is obtained. After 16 h, the amount of mezcaline falls below the detection limit.  
4. The polymer conjugate I however, showed and entirely different excretion profile: Using the crude 
polymer, mezcaline is excreted continuously over 17 days in the 24h pooled urine (average of 5 
animals, in 4 the amount was below detection limit after 17 days, in one animal after 21 days.) 
after s.c. injection. Initially about 15 ɣ are excreted, overall not more than 250 ɣ. 
5. Investigating the direct conjugate without the biodegradable linker, no basic excretion products 
are detected (data not shown). 
 
 
                                                        
12 notably, Jatzkewitz here clearly introduces the concept of a physiologicially cleavable linker between drug 
and carrier, necessary for the release of he active component. This is probably the first mentioning of the 
polymeric pro-drug concept still at the core of some many research projects today.  
13 the selection of different compounds is an excellent showcase how to select control experiments. Free drug, 
free drug plus polymer (non-conjugated) and polymer-drug conjugate with a non-cleavable linker would also 





Figure 1: Cut-outs from ascending paper chromatograms of urine extracts of a white mouse after s.c. 
injection of different mezcaline-containing substances with 1.7 mg mezcaline equivalents. (Test: lower spot 
= 20 ɣ Mez, upper spot = 30 ɣ gly-leu-mez; ─ = no urine obtained.) 
 
 
The described data refer to s.c. injection. After i.p. injection, all substances give similar excretion patterns 
with the exception of the conjugate I. For the latter, while the total amount of excreted mezcalin was 
similar, the amount of excreted mezcalin dropped below detection limit already after 9 days14 (average of 
3 animals, all gave negative result after 9 days). An estimate on the toxicity of the injected substances can 
be find in Table 1. 
 
Animals that received I were sometimes languid. The non-surviving animals died 1-3 days p.i. Three animals 
were investigated post mortem by Dr. Herz, Pharmacological Institute of the University Munich. The only 
pathological change found was a pleural exudate. 
 
The conjugate I exhibits a considerable toxicity upon i.p. injection (Table 1). 
 
Table 1: Mortality of white mice (37-42 g bodyweight) after s.c. and i.p. injection of different mezcaline 









# animals  
died thereof 
2 mg mez-HCl 4 0 10 1 
3.4 mg gly-leu-mez-HCl 5 0 4 1 
3.4 mg gly-leu-mez-HCl + 16 mg PVP-COOH 4 0 8 2 
20 mg PVP-CO-gly-leu-mez I 7 2 11 8 
24 mg PVP-CO-mez  10 2 11 5 
 
                                                     
14 This observation most likely reflects that he fact that i.p. leads to a faster uptake into the bloodstream as 
compared to s.c. administration 
detectable amount of basic substance (mezcaline) in urine after 





Looking at the obtained results with respect to the most important substance described herein, the 
polymer-peptamine conjugate I, it is clear that the physiologically active constituent of I, the gly-L-leu-mez 
is metabolized so quickly, that it seems unlikely that its physiological activity would differ from mezcalin. 
This corroborates earlier finding by others. 
 
Guggenheim described in 1913 that glycyl-tyramine and glycyl-histamine act like the free amines but are 
less toxic.(14) He assumed that the peptamine is metabolized in the animal organism. The correctness of 
this assumption was later confirmed, when Abderhalden found that D,L-leucyl-tyramine is cleaved 
asymmetrically by intestinal and pancreatic fluids.(15) 
 
Furthermore, our results show that the in vivo cleavage of mezcaline from the peptamine, as mentioned 
initially, is a prerequisite for the specific enzymatic degradation, and therefore, the ability of I to act as a 
depot. Without the biodegradable linker, no mezcalin can be detected in the urine of the treated animals. 
 
Regarding the mechanism of action, two possibilities appear reasonable. 
1. Mezcalin is cleaved from I as fast as it is cleaved from gly-L-leu-mez while the high molar mass 
carrier, which comprises 89% from poly(vinylpyrrolidone) (PVP)(12), constitutes the depot due to 
is special interaction with basic substances. In this case, co-injection of the carrier and the unbound 
peptamine should result in the same rate of mezcaline excretion. This is not the case (Fig. 1). Similar 
to histamine, mezcaline shows no affinity to PVP(6) and it remains only the alternative described 
below.  
2. The enzymatic release of mezcalin from the polymer occurs slowly over the course of days. 
 
In the latter case, the cleavage should be dependent, inter alia, on the resorption. The resorption, on the 
other hand, depends, among other parameters, on the molar mass of the injected substance as well as the 
route of administration. Therefore, the different mezcaline excretion between s.c. injection and i.p. 
administration can be understood. By determination of location and kind of enzyme (proteinase?, 
peptidase?) the circumstance could be understood in detail. 
The resorption may also be responsible for the observation that only 15-20% of the administered mezcalin 
was excreted as free mezcalin, while Block(3,4) found 80% excreted in the urine after injection. However, 
it is also possible, that the degree of detoxification is higher with prolonged exposure of smaller doses. It 
may be particularly interesting for the pharmacist and the pharmacologist whether the toxicity of I upon 
i.p. injection is due to the fact that this administration mimics a continuous i.v. injection or due to the 
properties of the injected polymer conjugate I. The comparison of the toxicity between I and the non-
biodegradable conjugate should inform about this, because I and the non-degradable conjugate only differ 
in its enzymatic degradability. Table 1 only approximates the actual toxicities but it appears reasonable to 
state that the macromolecular component significantly adds to the toxicity of the conjugates. In any case, 
it plays an important role, in particular from a pharmaceutical point of view. Apart from the fact that the 
components of the carrier may be detrimental for the organism, macromolecules that exceed a certain size 
cannot be eliminated from it.(5) This is likely the case for a 
part of the polymer conjugate synthesized by us, as the 
constituent polymer certainly suffers from a broad molar 
mass distribution (Box 5). On the other hand, it is necessary 
that a certain minimum molar mass is exceeded to enable a 
prolonged residence time in the organism which is necessary 
to allow a form of depot effect. Therefore, a suitable 
fractionation of the molar mass distribution and a suitable 
drug loading (which, in our case, should be readily achieved 
by variation of the acrylic acid content of the copolymer)15 
with a suitable drug will likely to govern the pharmaceutical 
aspects. This suitable drug could also be an endogenous compound of the primary amine type, for example 
the biogenic amines histamine, arterenol and serotonin, the physiologically active amino acid thyroxin or 
                                                        
15 However, the problem of the vastly different copolymerization parameters of VP and AA would still remain. 
Box 5: Gel permeation chromatography 
was not available at this time, but 
Jatzekwitz is certainly correct to assume 
the polymers will have likely have a 
dispersity of around 2, typical for free 
radical polymerization (see also Tutorial 
Figure 1), even though no 




the peptide hormone of the posterior pituitary oxytocin or vasopressin. Hence, we transition to the 
viewpoint of the biochemist, who will view the macromolecular carrier as a protein of low component 
yield16 and mezcaline as one of the mentioned components of the primary amine-type. The biochemist will 
ponder the question, whether I is a model for the “bound form” of histamine or for van Dyke’s(16) “mother-
protein” of the hormones found in the posterior pituitary or whether biogenic amines and peptide 
hormones are incorporated this tightly into suitable proteins or cellular structures without covalent bonds. 
An answer to this question cannot be given to date and is not expected from the biochemical mechanism 
of model substances. It can only be shown that the known biochemical mechanism, i.e. that an inactive 
precursor (e.g. pro-enzyme, hypertensinogen17, fibrinogen) of a physiological active substance is activated 
through an enzyme, is also transferable to biogenic amines, possibly also to peptide hormones in the 
combination with proteins18.  Therefore, when assessing the biological activity of bound forms, the factor 
time needs to be considered. The issue, that biogenic amines are active in the combination with proteins, 
possibly in a modified manner, is also interesting in a different context.  
It is known, that certain basic substances, including biogenic amines, can elicit psychological changes in 
humans which are similar to some forms of schizophrenia. Hence, Buscaino et al.(17) attribute toxic 
substances of basic nature which are presumably formed in a derailed metabolism, to be responsible for 
the formation of these mental disorders and Woolley et al.(18) recently considered lower levels of the 
endogenous biogenic amine serotonin as cause. Therefore, if one is searching for basic compounds in 
schizophrenic patients, one shall not forget proteins, into which these compounds may be incorporated. By 
administration of a depot-serotonin according to the present contribution, one may test Wooley´s 
hypothesis. 
 
It will be very difficult to successfully address the problem of the somatology of psychological disorders as 
long as it remains an equation with multiple unknowns. One may eliminate one unknown using a 
pharmacological approach with substances, which interfere with the psyche through the soma just as 
mezcaline does. 
 
In contrast to those of mezcaline, the properties of I would allow us to single-out an issue within a more 
complex problem. While mezcaline elicits an acute intoxication, I allows eliciting an chronic intoxication in 
humans. While the acute mezcaline intoxication generally does not cause psychological damage, it would 
be important to know how long it takes a human, who is psychologically disturbed for 14 days by 
administration of I, to return to mental equilibrium. However, also the answer to this question by 
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16 this is a direct translation of the original, which reads „im   makromolekularen    Träger   ein   Protein   von    
geringem  Baustein-Umsatz […] sieht.“ The author of this translation is not quite sure what this is supposed to 
mean in this context. 
17 hypertensinogen is today called angiotensinogen 
18 again, here Jatzkewitz pioneers the idea of a polymeric prodrug. 
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